UroGen Pharma （URGN.US）2Q24 Recap： Jelmyto sales flat； operating expenses edge higher ahead of NDA completion

13 August 2024 | 4:05PM EDT UroGen Pharma (URGN): 2024 Recap: Jelmyto sales flat; operating expenses edge higher ahead of NDA completion Jelmyto sales flat y/y as focus remains on completing the rolling NDA submission for UGN-102. URGN reported its 2Q24 results with topline sales of Jelmyto coming in at $21.8mn, in-line with our estimates of $22mn but below Visible Alpha Consensus Data of $23.5mn. The company said its commercial asset faced some headwinds related to 340B and other Medicaid/Medicare discount ...